INTRODUCTION: Published data support the safety of glatiramer acetate in patients with multiple sclerosis who are pregnant or breastfeeding, but long-term data are limited. OBJECTIVE: We aimed to assess pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate. METHODS: In-utero glatiramer acetate-exposed postmarketing pregnancy reports from 2019 to 2021 were extracted from Teva's pharmacovigilance database. Pregnancy data acquired prior to knowledge of pregnancy outcome or detection of congenital malformation (prospective reports) were used to estimate pregnancy and infant outcome rates for glatiramer acetate 20- and 40-mg/mL exposure. A subgroup of cases completed follow-up questionnaires and were analyzed separately. RESULTS: Prospective cases with 702 fetuses had known outcomes with 647 (92.2%) live births, 47 (6.7%) spontaneous abortions, 4 (0.6%) induced abortions, 2 (0.3%) ectopic pregnancies, and 2 (0.3%) fetal deaths. Rates of major congenital malformation (1.1%), preterm births (7.2%), and low/very low birth weight (4.8%), and parameters of growth were within background rates. No infant developmental delay was reported. Overall, pregnancy and infant outcomes were similar across glatiramer acetate doses. CONCLUSIONS: Maternal exposure to glatiramer acetate does not appear to be related to adverse pregnancy, fetal, or infant outcomes. These data further support the safety of both glatiramer acetate 20-mg/mL and 40-mg/mL treatments during pregnancy and breastfeeding.
INTRODUCTION: Published data support the safety of glatiramer acetate in patients with multiple sclerosis who are pregnant or breastfeeding, but long-term data are limited. OBJECTIVE: We aimed to assess pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate. METHODS: In-utero glatiramer acetate-exposed postmarketing pregnancy reports from 2019 to 2021 were extracted from Teva's pharmacovigilance database. Pregnancy data acquired prior to knowledge of pregnancy outcome or detection of congenital malformation (prospective reports) were used to estimate pregnancy and infant outcome rates for glatiramer acetate 20- and 40-mg/mL exposure. A subgroup of cases completed follow-up questionnaires and were analyzed separately. RESULTS: Prospective cases with 702 fetuses had known outcomes with 647 (92.2%) live births, 47 (6.7%) spontaneous abortions, 4 (0.6%) induced abortions, 2 (0.3%) ectopic pregnancies, and 2 (0.3%) fetal deaths. Rates of major congenital malformation (1.1%), preterm births (7.2%), and low/very low birth weight (4.8%), and parameters of growth were within background rates. No infant developmental delay was reported. Overall, pregnancy and infant outcomes were similar across glatiramer acetate doses. CONCLUSIONS: Maternal exposure to glatiramer acetate does not appear to be related to adverse pregnancy, fetal, or infant outcomes. These data further support the safety of both glatiramer acetate 20-mg/mL and 40-mg/mL treatments during pregnancy and breastfeeding.
Authors: Ai-Lan Nguyen; Eva Kubala Havrdova; Dana Horakova; Guillermo Izquierdo; Tomas Kalincik; Anneke van der Walt; Murat Terzi; Raed Alroughani; Pierre Duquette; Marc Girard; Alexandre Prat; Cavit Boz; Patrizia Sola; Diana Ferraro; Alessandra Lugaresi; Jeannette Lechner-Scott; Michael Barnett; Francois Grand'Maison; Pierre Grammond; Cristina Ramo-Tello; Recai Turkoglu; Pamela McCombe; Eugenio Pucci; Maria Trojano; Franco Granella; Daniele Spitaleri; Vincent Van Pesch; Aysun Soysal; Celia Oreja-Guevara; Freek Verheul; Steve Vucic; Suzanne Hodgkinson; Mark Slee; Radek Ampapa; Julie Prevost; Jose Luis Sanchez Menoyo; Olga Skibina; Claudio Solaro; Javier Olascoaga; Cameron Shaw; Klaus Gregaard Madsen; Kerisha Naidoo; Robert Hyde; Helmut Butzkueven; Vilija Jokubaitis Journal: Mult Scler Relat Disord Date: 2019-01-03 Impact factor: 4.339
Authors: Kristen M Krysko; Alice Rutatangwa; Jennifer Graves; Ann Lazar; Emmanuelle Waubant Journal: JAMA Neurol Date: 2020-03-01 Impact factor: 18.302
Authors: Riley Bove; Sura Alwan; Jan M Friedman; Kerstin Hellwig; Maria Houtchens; Gideon Koren; Ellen Lu; Thomas F McElrath; Penelope Smyth; Helen Tremlett; A Dessa Sadovnick Journal: Obstet Gynecol Date: 2014-12 Impact factor: 7.661
Authors: Annette Langer-Gould; Jessica B Smith; Kathleen B Albers; Anny H Xiang; Jun Wu; Erica H Kerezsi; Keeli McClearnen; Edlin G Gonzales; Amethyst D Leimpeter; Stephen K Van Den Eeden Journal: Neurology Date: 2020-04-13 Impact factor: 9.910
Authors: Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca Journal: Neurology Date: 2019-02-15 Impact factor: 9.910
Authors: Marta Giannini; Emilio Portaccio; Angelo Ghezzi; Bahia Hakiki; Luisa Pastò; Lorenzo Razzolini; Elisa Piscolla; Laura De Giglio; Carlo Pozzilli; Damiano Paolicelli; Maria Trojano; Maria Giovanna Marrosu; Francesco Patti; Loredana La Mantia; Gianluigi Mancardi; Claudio Solaro; Rocco Totaro; Maria Rosaria Tola; Giovanna De Luca; Alessandra Lugaresi; Lucia Moiola; Vittorio Martinelli; Giancarlo Comi; Maria Pia Amato Journal: BMC Neurol Date: 2012-10-22 Impact factor: 2.474